Table 8.
Distribution of MSH2 and EPCAM expressions in lesions from EPCAM3′-end deletion carriers.
| Lesion From EPCAM 3′-End Deletion Carriers |
MSH2 Expression | p-Value | EPCAM Expression | p-Value * | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (−) | (+) | Total | (−) | (+) | Total | |||||
| I | NI | |||||||||
| CL | FL | |||||||||
| 0.000 | 0.510 * | |||||||||
| Malignant neoplasms | ||||||||||
| Location | ||||||||||
| Stomach | 1 | 0 | 0 | 0 | 0 | 1 | ||||
| Duodenum | 1 | 0 | 0 | 0 | 0 | 1 | ||||
| Colon and rectum | 19 | 0 | 10 | 0 | 0 | 9 | ||||
| Endometrium | 1 | 0 | 0 | 0 | 0 | 1 | ||||
| Ovary | 1 | 0 | 0 | 0 | 0 | 1 | ||||
| 23 | 0 | 23 | 10 | 0 | 0 | 13 | 23 | |||
| Colorectal polyps | ||||||||||
| Histology | ||||||||||
| TA | 6 | 0 | 1 | 2 | 0 | 3 | ||||
| TVA | 1 | 0 | 0 | 0 | 0 | 1 | ||||
| HP | 0 | 2 | 0 | 0 | 0 | 2 | ||||
| SSL | 7 | 0 | 1 | 2 | 0 | 4 | ||||
| TSA | 2 | 0 | 0 | 1 | 0 | 1 | ||||
| 16 | 2 | 18 | 2 | 5 | 0 | 11 | 18 | |||
| Precursor lesions extra-GI origin | ||||||||||
| Location | ||||||||||
| Cervix | 0 | 2 | 2 | 0 | 0 | 2 | 0 | 2 | ||
| 43 | 43 | |||||||||
| Mutated gene | 0.598 | 0.665 * | ||||||||
| EPCAM | 34 | 4 | 15 | 0 | 0 | 21 | ||||
| EPCAM-MSH2 | 5 | 0 | 2 | 0 | 0 | 3 | ||||
| 39 | 4 | 43 | 17 | 0 | 0 | 24 | 43 | |||
Abbreviations: −, negative; +, positive; I, informative; and NI, noninformative. * EPCAM p-value was calculated on 41 cases, because noninformative cervical lesions were eliminated.